| Life science innovation and the restructuring of the pharmaceutical industry: Merger, acquisition and strategic alliance behaviour of large firms J Mittra Technology Analysis & Strategic Management 19 (3), 279-301, 2007 | 119 | 2007 |
| The new health bioeconomy: R&D policy and innovation for the twenty-first century J Mittra Springer, 2015 | 57 | 2015 |
| Twenty-first century bioeconomy: Global challenges of biological knowledge for health and agriculture D Wield, R Hanlin, J Mittra, J Smith Science and Public Policy 40 (1), 17-24, 2013 | 55 | 2013 |
| Evolution of business models in regenerative medicine: effects of a disruptive innovation on the innovation ecosystem G Banda, J Tait, J Mittra Clinical therapeutics 40 (7), 1084-1094, 2018 | 49 | 2018 |
| Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells J Mittra, J Tait, M Mastroeni, ML Turner, JC Mountford, K Bruce New biotechnology 32 (1), 180-190, 2015 | 42 | 2015 |
| Analysing stratified medicine business models and value systems: innovation-regulation interactions J Mittra, J Tait New biotechnology 29 (6), 709-719, 2012 | 40 | 2012 |
| Unpacking the concept of bioeconomy: Problems of definition, measurement, and value J Mittra, G Zoukas Science & Technology Studies 33 (1), 2-21, 2020 | 37 | 2020 |
| From maturity to value-added innovation: lessons from the pharmaceutical and agro-biotechnology industries J Mittra, J Tait, D Wield Trends in biotechnology 29 (3), 105-109, 2011 | 33 | 2011 |
| Regenerative medicine: business models, venture capital and the funding gap OM Omidvar, D Castle, M James Innogen Institute Report, 2014 | 27 | 2014 |
| Repairing the ‘Broken Middle’of the Health Innovation Pathway: Exploring Diverse Practitioner Perspectives on the Emergence and Role of ‘Translational Medicine’ J Mittra Science & Technology Studies 26 (3), 103-123, 2013 | 22 | 2013 |
| TRANSLATIONAL MEDICINE J Mittra, CP Milne CRC Press Taylor & Francis Group., 2013 | 20 | 2013 |
| Impact of the life sciences on organisation and management of R&D in large pharmaceutical firms J Mittra International Journal of Biotechnology 10 (5), 416-440, 2008 | 19 | 2008 |
| Marginalising ‘eugenic anxiety’through a rhetoric of ‘liberal choice’: a critique of the House of Commons Select Committee Report on reproductive technologies J Mittra New Genetics and Society 26 (2), 159-179, 2007 | 16 | 2007 |
| Industry challenges J Tait, J Mittra | 16 | 2004 |
| New Health Bioeconomy J Mittra, J Mittra Springer Verlag, 2016 | 15 | 2016 |
| Predictive genetic information and access to life assurance: The poverty of ‘genetic exceptionalism’ J Mittra BioSocieties 2 (3), 349-373, 2007 | 15 | 2007 |
| The socio-political economy of pharmaceutical mergers: A case study of Sanofi and Aventis J Mittra Technology Analysis & Strategic Management 18 (5), 473-496, 2006 | 15 | 2006 |
| ‘Genetic exceptionalism’and precautionary politics: Regulating for uncertainty in Britain's genetics and insurance policy process J Mittra Science and Public Policy 33 (8), 585-600, 2006 | 15 | 2006 |
| Introduction to translational medicine J Mittra, CP Milne Translational medicine: The future of therapy, 3-16, 2013 | 13 | 2013 |
| Conceptualising and practising multiple knowledge interactions in the life sciences D Wield, J Tait, J Chataway, J Mittra, M Mastroeni Technological Forecasting and Social Change 116, 308-315, 2017 | 12 | 2017 |
